|3 Months Ended|
Mar. 31, 2023
Equity Incentive Plan
On June 16, 2022, the stockholders of the Company approved the Amended and Restated 2020 Equity Incentive Plan (the “Plan”) to increase the total number of shares of common stock reserved for issuance under the Plan by 1,250,000 shares to 2,062,500 total shares issuable under the Plan. As of March 31, 2023, 442,853 shares of common stock were available for future grants under the Plan. The table below sets forth the outstanding options to purchase common shares under the Plan:
There were no options issued during the three months ended March 31, 2023. As of March 31, 2023 the aggregate intrinsic value of options outstanding was $57,590.
The Company recognized share-based compensation expense related to stock options during the three months ended March 31, 2023 and 2022, of $161,697 and $131,906, respectively. The unrecognized compensation expense for stock options at March 31, 2023 was $952,376.
Stock Options for Unregistered Securities
In addition to the stock options issued under the Plan, and in conjunction with the IPO, the Company granted non-qualified stock options to purchase 292,500 shares of common stock as provided for in the President’s employment agreement (the “President Options”). The President Options are exercisable within 10 years of the date of grant at $10.00 per share, were 100% vested at the grant date and have a remaining contractual term of 7.72 years. As of March 31, 2023, there was no unrecognized compensation expense related to these options as they were 100% vested upon issuance. The shares of common stock issuable upon exercise of the President Options will be unregistered, and the option agreement does not include any obligation on the part of the Company to register such shares of common stock. Consequently, the Company
has not recognized a contingent liability associated with registering the securities for the arrangement. As of March 31, 2023, the aggregate intrinsic value of the President Options was $0.
In conjunction with the IPO, the Company granted the underwriters warrants to purchase 172,500 shares of common stock at an exercise price of $12.50 per share. The warrants became 100% exercisable on December 21, 2021.
In conjunction with the Offering in September 2022, the Company granted the Underwriter warrants to purchase 500,000 shares of common stock at an exercise price of $0.625 per share. The warrants became 100% exercisable on March 18, 2023.
There is no unrecognized compensation expense for these awards as of March 31, 2023. The table below sets forth the outstanding warrants to purchase common shares:
As of March 31, 2023, the aggregate intrinsic value of the warrants outstanding was $0.
The entire disclosure for share-based payment arrangement.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
No definition available.